These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28506993)

  • 1. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.
    Haston S; Pozzi S; Carreno G; Manshaei S; Panousopoulos L; Gonzalez-Meljem JM; Apps JR; Virasami A; Thavaraj S; Gutteridge A; Forshew T; Marais R; Brandner S; Jacques TS; Andoniadou CL; Martinez-Barbera JP
    Development; 2017 Jun; 144(12):2141-2152. PubMed ID: 28506993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.
    Gaston-Massuet C; Andoniadou CL; Signore M; Jayakody SA; Charolidi N; Kyeyune R; Vernay B; Jacques TS; Taketo MM; Le Tissier P; Dattani MT; Martinez-Barbera JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(28):11482-7. PubMed ID: 21636786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors.
    Garcia-Lavandeira M; Saez C; Diaz-Rodriguez E; Perez-Romero S; Senra A; Dieguez C; Japon MA; Alvarez CV
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E80-7. PubMed ID: 22031517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOX2 is sequentially required for progenitor proliferation and lineage specification in the developing pituitary.
    Goldsmith S; Lovell-Badge R; Rizzoti K
    Development; 2016 Jul; 143(13):2376-88. PubMed ID: 27226320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
    Brastianos PK; Santagata S
    Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 7. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.
    Gonzalez-Meljem JM; Haston S; Carreno G; Apps JR; Pozzi S; Stache C; Kaushal G; Virasami A; Panousopoulos L; Mousavy-Gharavy SN; Guerrero A; Rashid M; Jani N; Goding CR; Jacques TS; Adams DJ; Gil J; Andoniadou CL; Martinez-Barbera JP
    Nat Commun; 2017 Nov; 8(1):1819. PubMed ID: 29180744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.
    Gualtieri A; Kyprianou N; Gregory LC; Vignola ML; Nicholson JG; Tan R; Inoue SI; Scagliotti V; Casado P; Blackburn J; Abollo-Jimenez F; Marinelli E; Besser REJ; Högler W; Karen Temple I; Davies JH; Gagunashvili A; Robinson ICAF; Camper SA; Davis SW; Cutillas PR; Gevers EF; Aoki Y; Dattani MT; Gaston-Massuet C
    Nat Commun; 2021 Apr; 12(1):2028. PubMed ID: 33795686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
    Aylwin SJ; Bodi I; Beaney R
    Pituitary; 2016 Oct; 19(5):544-6. PubMed ID: 26115708
    [No Abstract]   [Full Text] [Related]  

  • 10. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch-Dependent Pituitary SOX2(+) Stem Cells Exhibit a Timed Functional Extinction in Regulation of the Postnatal Gland.
    Zhu X; Tollkuhn J; Taylor H; Rosenfeld MG
    Stem Cell Reports; 2015 Dec; 5(6):1196-1209. PubMed ID: 26651607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX2 is required independently in both stem and differentiated cells for pituitary tumorigenesis in
    Moncho-Amor V; Chakravarty P; Galichet C; Matheu A; Lovell-Badge R; Rizzoti K
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33574062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential.
    Andoniadou CL; Matsushima D; Mousavy Gharavy SN; Signore M; Mackintosh AI; Schaeffer M; Gaston-Massuet C; Mollard P; Jacques TS; Le Tissier P; Dattani MT; Pevny LH; Martinez-Barbera JP
    Cell Stem Cell; 2013 Oct; 13(4):433-45. PubMed ID: 24094324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
    Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hes1 and Hes5 are required for differentiation of pituicytes and formation of the neurohypophysis in pituitary development.
    Goto M; Hojo M; Ando M; Kita A; Kitagawa M; Ohtsuka T; Kageyama R; Miyamoto S
    Brain Res; 2015 Nov; 1625():206-17. PubMed ID: 26348989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
    Martinez-Barbera JP
    J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.